Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.00.232 on May 2 2005

Journal of Clinical Oncology, Vol 23, No 16 (June 1), 2005: pp. 3706-3712
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kabbinavar, F. F.
Right arrow Articles by Sarkar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kabbinavar, F. F.
Right arrow Articles by Sarkar, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer

Fairooz F. Kabbinavar, Julie Hambleton, Robert D. Mass, Herbert I. Hurwitz, Emily Bergsland, Somnath Sarkar

From the University of California Los Angeles, Los Angeles; Genentech Inc, South San Francisco; University of California San Francisco, San Francisco, CA; Duke University, Durham, NC

Address reprint requests to Somnath Sarkar, PhD, Medical Affairs, Genentech Inc, One DNA Way, South San Francisco, CA 94080; e-mail: sarkar.somnath{at}gene.com

PURPOSE: Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti–vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluourouracil (FU)/leucovorin (LV; IFL). Three randomized clinical studies have evaluated bevacizumab in combination with FU/LV alone. A combined analysis of raw data from these studies was performed to better assess the efficacy of bevacizumab with FU/LV.

PATIENTS AND METHODS: The analysis used primary efficacy data from three independent studies, including 241 patients in a combined control group receiving either FU/LV or IFL and 249 patients receiving FU/LV/bevacizumab (5 mg/kg once every 2 weeks). The efficacy data included response rate, progression-free survival, and overall survival.

RESULTS: The median duration of survival was 17.9 months in the FU/LV/bevacizumab group, compared with 14.6 months in the combined control group, corresponding to a hazard ratio for death of 0.74 (P = .008). The median duration of progression-free survival was 8.8 months in the FU/LV/bevacizumab group, compared with 5.6 months in the combined control group, corresponding to a hazard ratio for disease progression of 0.63 (P ≤ .0001). The addition of bevacizumab also improved the response rate (34.1% v 24.5%; P = .019).

CONCLUSION: The addition of bevacizumab to FU/LV provides a statistically significant and clinically relevant benefit to patients with previously untreated metastatic colorectal cancer.

Supported by Genentech Inc.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Welch, K. Spithoff, R. B. Rumble, J. Maroun, and the Gastrointestinal Cancer Disease Site Group
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Ann. Onc., November 25, 2009; (2009) mdp533v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. DiBartolomeo, M.-A. Mazier, J.-L. Canon, V. Georgoulias, M. Peeters, et al.
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
Ann. Onc., November 1, 2009; 20(11): 1842 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. Damjanov, J. Weiss, and D. G. Haller
Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease
Oncologist, October 1, 2009; 14(10): 963 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68.
[Abstract] [PDF]

Home page
 The OncologistHome page
M. Kozloff, M. U. Yood, J. Berlin, P. J. Flynn, F. F. Kabbinavar, D. M. Purdie, M. A. Ashby, W. Dong, M. M. Sugrue, A. Grothey, et al.
Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
Oncologist, September 1, 2009; 14(9): 862 - 870.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. A. Poultsides, E. L. Servais, L. B. Saltz, S. Patil, N. E. Kemeny, J. G. Guillem, M. Weiser, L. K.F. Temple, W. D. Wong, and P. B. Paty
Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment
J. Clin. Oncol., July 10, 2009; 27(20): 3379 - 3384.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al.
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Tol, M. Koopman, A. Cats, C. J. Rodenburg, G. J.M. Creemers, J. G. Schrama, F. L.G. Erdkamp, A. H. Vos, C. J. van Groeningen, H. A.M. Sinnige, et al.
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
N. Engl. J. Med., February 5, 2009; 360(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro
Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
Ann. Onc., January 1, 2009; 20(1): 5 - 16.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey, M. M. Sugrue, D. M. Purdie, W. Dong, D. Sargent, E. Hedrick, and M. Kozloff
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
J. Clin. Oncol., November 20, 2008; 26(33): 5326 - 5334.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Benetti, A. Berenzi, M. Gambarotti, E. Garrafa, M. Gelati, E. Dessy, N. Portolani, T. Piardi, S. M. Giulini, A. Caruso, et al.
Transforming Growth Factor-{beta}1 and CD105 Promote the Migration of Hepatocellular Carcinoma-Derived Endothelium
Cancer Res., October 15, 2008; 68(20): 8626 - 8634.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Meulenbeld, L. N. van Steenbergen, M. L. G. Janssen-Heijnen, V. E. P. P. Lemmens, and G. J. Creemers
Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004
Ann. Onc., September 1, 2008; 19(9): 1600 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.-S. Yang, F. Rivera, et al.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
J. Clin. Oncol., April 20, 2008; 26(12): 2013 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. K. Oldham and R. O. Dillman
Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
J. Clin. Oncol., April 10, 2008; 26(11): 1774 - 1777.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, et al.
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Ann. Onc., April 1, 2008; 19(4): 734 - 738.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al.
Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy
J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Martin and R. Schilder
Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition
J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Giaccone
The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A.-R. Hanauske, J. Cassidy, J. Sastre, C. Bolling, R. J. Jones, A. Rakhit, S. Fettner, U. Brennscheidt, A. Feyereislova, and E. Diaz-Rubio
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 15, 2007; 13(2): 523 - 531.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W Ichikawa and Y Sasaki
Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients
Ann. Onc., November 1, 2006; 17(11): 1665 - 1672.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Heidemann, D G Binion, W Domschke, and T Kucharzik
Antiangiogenic therapy in human gastrointestinal malignancies.
Gut, October 1, 2006; 55(10): 1497 - 1511.
[Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. J. O'Dwyer
The Present and Future of Angiogenesis-Directed Treatments of Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 992 - 998.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Shayan, M. G. Achen, and S. A. Stacker
Lymphatic vessels in cancer metastasis: bridging the gaps
Carcinogenesis, September 1, 2006; 27(9): 1729 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. J. Meropol
Turning Point for Colorectal Cancer Clinical Trials
J. Clin. Oncol., July 20, 2006; 24(21): 3322 - 3324.
[Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem
Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges
J. Clin. Oncol., July 20, 2006; 24(21): 3325 - 3327.
[Full Text] [PDF]

Home page
 JCOHome page
T. Gruenberger, B. Gruenberger, and W. Scheithauer
Neoadjuvant Therapy With Bevacizumab
J. Clin. Oncol., June 1, 2006; 24(16): 2592 - 2593.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al.
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients.
Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
D. R. Yance Jr and S. M. Sagar
Targeting Angiogenesis With Integrative Cancer Therapies
Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29.
[Abstract] [PDF]

Home page
 Ann OncolHome page
G. A. P. Hospers, M. Schaapveld, J. W. R. Nortier, J. Wils, A. van Bochove, R. S. de Jong, G. J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, et al.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P.-L. Tremblay, F. Berthod, L. Germain, and F. A. Auger
In Vitro Evaluation of the Angiostatic Potential of Drugs Using an Endothelialized Tissue-Engineered Connective Tissue
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 510 - 516.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online